Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF)
patients to an increased risk of stroke. This study describes the real-world discontinuation …

Introduction Continuous usage of direct oral anticoagulants (DOACs) among nonvalvular
atrial fibrillation (NVAF) patients is essential to maintain stroke prevention. We examined …

Background Limited data are available about the real‐world safety of non‐vitamin K
antagonist oral anticoagulants (NOAC s). Objectives To compare the major bleeding risk …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs)
available for stroke prevention in non valvular atrial fibrillation (NVAF). There are limited …

Background Studies have shown that patients with non-valvular atrial fibrillation (NVAF) who
discontinue oral anticoagulants (OACs) are at higher risk of complications such as stroke …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Objective: To compare real-world persistence and discontinuation among non-valvular atrial
fibrillation (NVAF) patients on rivaroxaban and dabigatran in the US. Methods: A large …

This study examined characteristics and treatment persistence among patients prescribed
oral anticoagulants (OACs) for stroke prevention in non-valvular atrial fibrillation (NVAF). We …

A retrospective cohort analysis of the US MarketScan claims databases was performed to
compare persistence and discontinuation rates between the vitamin K antagonist warfarin …